15 July 2013
Rhabdomyosarcoma of the breast – a rare malignancy
Suresh J. BhosaleA, Ashok Y. KshirsagarE, Soniya R. SulhyanF, Sanjitsingh R. SulhyanBDOI: 10.12659/AJCR.883976
Am J Case Rep 2013; 14:250-252
Abstract
Background: Primary nonepithelial malignancies of the breast include primary breast sarcomas, therapy-related breast sarcomas, the phyllodes tumors, and primary breast lymphomas. They account for less than 5% of all breast neoplasms.
Case Report: We report the case of a 60-year-old postmenopausal female diagnosed with rhabdomyosarcoma with infiltrating duct carcinoma. She was treated with modified radical mastectomy with axillary clearance and postoperative chemotherapy.
Conclusions: Primary rhabdomyosarcoma of the breast in adults is extremely rare. Rhabdomyosarcomas in adults account for less than 3% of all adult primary soft-tissue sarcomas.
Primary breast sarcomas usually present as large painless breast lumps with no associated skin and nipple changes or axillary lymphadenopathy; they are more aggressive and have more rapid growth than epithelial malignancies or benign breast lesions. The tumor can grow to large size, around 5.8 cm. Affected patients are typically women in their 50 s (ranging from 17 to 89 years), but it is also seen in men.
The treatment of primary breast sarcomas requires a multidisciplinary approach. Surgery remains the mainstay of therapy. Chemotherapy has no clearly defined role in primary breast or soft-tissue sarcomas.
The prognosis of primary breast sarcomas depends on the histologic grade and size of the tumor. They spread locally and hematogenously, but they are not usually associated with axillary lymphadenopathy.
Keywords: Rhabdomyosarcoma, Breast, Rhabdomyosarcoma breast
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947163
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949194
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948731
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947386
Most Viewed Current Articles
21 Jun 2024 : Case report
101,839
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
54,458
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
38,088
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,936
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200